Apollomics Inc Cl A (APLM) Stock Price, Quote & News

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule mu...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 209 4055

Fax: 650 288 1674

Website: www.apollomicsinc.com

Address:

989 East Hillsdale Blvd., Suite 220, Foster City, United States

MasonRe1 Jul. 15 at 3:48 PM

$APLM Late-stage oncology pipeline: Its lead drug candidate, vebreltinib (APL-101), targets cancers driven by c-MET alterations, an area of significant unmet medical need. Success in this niche could create meaningful commercial value.

0 · Reply

topstockalerts Jul. 15 at 3:01 PM

Top Gainers PT2 $KUST $TGHL $CNXU $VTAK $APLM

0 · Reply

ViktoriaCloud Jul. 15 at 2:55 PM

$APLM price target?

0 · Reply

LuigiV_ Jul. 14 at 7:29 PM

$SDOT $STFS $MOVE.X $APLM costs

0 · Reply

LQQKER_INSIDER Jul. 13 at 9:10 PM

$APLM Now down over 31% in 3 weeks. lol So E-A-S-Y !!!

0 · Reply

LuigiV_ Jul. 13 at 6:46 PM

$MRDN $APLM $BWAY feel about it

0 · Reply

Breton2018 Jul. 3 at 11:03 AM

$APLM Buyer for another trip to 20+

0 · Reply

TopSarge Jun. 29 at 2:25 PM

$APLM This is one I’m tracking

0 · Reply

LQQKER_INSIDER Jun. 24 at 2:24 PM

$APLM SHORT AT WILL! Easy Money! Too bad no options!

0 · Reply

ChazzyTrades Jun. 23 at 12:56 AM

$APLM nice close. Hopefully this thing rips

0 · Reply

Apollomics regains compliance with Nasdaq listing requirements

Jul 13, 2026, 8:00 AM EDT - 2 days ago

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

2026-06-25T16:00:28.000Z - 20 days ago

Apollomics Inc trading resumes

2026-06-25T15:55:20.000Z - 20 days ago

Apollomics Inc trading halted, volatility trading pause

2026-06-24T20:35:58.000Z - 20 days ago

Apollomics receives noncompliance notice from Nasdaq

Jun 24, 2026, 4:15 PM EDT - 20 days ago

Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

May 15, 2026, 8:00 AM EDT - 2 months ago

Apollomics Registration statement: Registration filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Apollomics Annual report: Q4 2025

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Apollomics Earnings release: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Apollomics Inc. Announces $2.0 Million Bridge Financing

2026-03-09T21:20:09.000Z - 4 months ago

Apollomics files to sell 279,775 Class A Ordinary shares for holders

Mar 9, 2026, 8:00 AM EDT - 4 months ago

Apollomics Registration statement: Registration Filing

2025-12-30T21:00:11.000Z - 7 months ago

Apollomics Inc trading resumes

2025-12-30T20:55:19.000Z - 7 months ago

Apollomics Inc trading halted, volatility trading pause

Dec 22, 2025, 4:05 PM EST - 7 months ago

Apollomics Reports First Half 2025 Financial Results

Dec 22, 2025, 3:00 PM EST - 7 months ago

Apollomics Earnings release: Q2 2025

2025-11-21T16:50:25.000Z - 8 months ago

Apollomics Inc trading resumes

2025-11-21T16:45:23.000Z - 8 months ago

Apollomics Inc trading halted, volatility trading pause

2025-11-19T22:45:12.000Z - 8 months ago

Apollomics announces settlement of Cayman litigation

Nov 19, 2025, 5:38 PM EST - 8 months ago

Apollomics Announces Settlement of Cayman Litigation

2025-11-18T16:15:24.000Z - 8 months ago

Apollomics Inc trading resumes

2025-11-18T16:10:11.000Z - 8 months ago

Apollomics Inc trading halted, volatility trading pause

Nov 17, 2025, 11:00 PM EST - 8 months ago

Apollomics Announces Changes to its Board of Directors and Composition of Committees

2025-10-31T14:11:03.000Z - 9 months ago

Apollomics Inc trading resumes

2025-10-31T14:06:22.000Z - 9 months ago

Apollomics Inc trading halted, volatility trading pause

2025-10-16T17:15:20.000Z - 9 months ago

Apollomics Inc trading resumes

2025-10-16T17:10:24.000Z - 9 months ago

Apollomics Inc trading halted, volatility trading pause

2025-10-15T18:45:14.000Z - 9 months ago

Apollomics says securities to remain listed on Nasdaq

Oct 15, 2025, 2:36 PM EDT - 9 months ago

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

2025-10-14T20:10:22.000Z - 9 months ago

nasdaq resumes trading in Apollomics

2025-10-14T10:00:33.000Z - 9 months ago

Apollomics reverses wind-up plans, provides operational update

Oct 13, 2025, 9:22 PM EDT - 9 months ago

Apollomics, Inc. Company Operational Continuity Update

2025-09-17T21:56:00.000Z - 10 months ago

Nasdaq halts Apollomics

NDAQ

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

$Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Dec 20, 2024, 8:00 AM EST - 1 year ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 10, 2024, 4:05 PM EST - 1 year ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 4, 2024, 4:05 PM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 10:00 AM EDT - 2 years ago

Apollomics Earnings release: Q2 2024

Aug 14, 2024, 6:00 AM EDT - 2 years ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 2 years ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 26, 2023, 8:50 AM EDT - 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Oct 7, 2022, 4:05 PM EDT - 4 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

MasonRe1 Jul. 15 at 3:48 PM

0 · Reply

topstockalerts Jul. 15 at 3:01 PM

Top Gainers PT2 $KUST $TGHL $CNXU $VTAK $APLM

0 · Reply

ViktoriaCloud Jul. 15 at 2:55 PM

$APLM price target?

0 · Reply

LuigiV_ Jul. 14 at 7:29 PM

$SDOT $STFS $MOVE.X $APLM costs

0 · Reply

LQQKER_INSIDER Jul. 13 at 9:10 PM

$APLM Now down over 31% in 3 weeks. lol So E-A-S-Y !!!

0 · Reply

LuigiV_ Jul. 13 at 6:46 PM

$MRDN $APLM $BWAY feel about it

0 · Reply

Breton2018 Jul. 3 at 11:03 AM

$APLM Buyer for another trip to 20+

0 · Reply

TopSarge Jun. 29 at 2:25 PM

$APLM This is one I’m tracking

0 · Reply

LQQKER_INSIDER Jun. 24 at 2:24 PM

$APLM SHORT AT WILL! Easy Money! Too bad no options!

0 · Reply

ChazzyTrades Jun. 23 at 12:56 AM

$APLM nice close. Hopefully this thing rips

0 · Reply

Harley6690 Jun. 22 at 10:09 PM

$APLM This is moving up very quietly

0 · Reply

SmartMoneyTradez Jun. 22 at 7:25 PM

$APLM Needs volume to squeeze shorts

0 · Reply

ChazzyTrades Jun. 22 at 7:04 PM

$APLM im in. Let’s do this 🚀🚀

0 · Reply

ChazzyTrades Jun. 22 at 6:04 PM

$APLM lol this is horrible bro. No matter what i buy i can’t win

0 · Reply

Stock_Catcher Jun. 18 at 5:25 PM

$BFLY new high of day too, $BESS $APLM $MDCX $KALA Thin setups im watching

0 · Reply

lars70 Jun. 6 at 10:49 PM

$APLM Im a buyer at 13 14 15

0 · Reply

SuperGreenToday Jun. 4 at 3:52 PM

$APLM

0 · Reply

AtlasAnalysis Apr. 16 at 2:24 PM

$APLM glued to support. Volume or catalyst turns it around to 20+

0 · Reply

DARKP00L Apr. 1 at 11:13 AM

$APLM 07:11 on Apr. 01 2026 Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30 #tradeideas

0 · Reply

Market Cap	31.21M
Revenue (ttm)	8.50M
Net Income (ttm)	-10.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-128.71%
Debt to Equity Ratio	0.00

Volume	166,500
Avg Vol	17,732
Day's Range	N/A - N/A
Shares Out	2.20M
Stochastic %K	24%
Beta	1.44
Analysts	Strong Buy
Price Target	$6.50